The latter two are considered promising therapeutic and diagnostic targets in acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS); in particular, the 1C-type lectin domain family 12 member A (CLEC12A) is an inhibitory receptor identified as a specific marker for CSC in acute myeloid leukaemia [64,65]. Here, CLEC12A is linked to myelodysplastic syndrome.